Dualyx specializes in the discovery and development of biological therapies aimed at treating autoimmune and rare diseases. The company focuses on creating immune modulators, particularly Treg-targeted therapies, which are designed to suppress unwanted autoimmune reactions in patients. By advancing these innovative treatments, Dualyx aims to provide lasting solutions for individuals suffering from autoimmune diseases, ultimately enabling medical professionals to offer effective cures.
MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.
Ermium Therapeutics is a biotechnology company based in Paris, France, focused on developing innovative therapies for auto-immune and inflammatory diseases. Founded in June 2019, the company centers its research on CXCR4, identified as a master regulator of inflammation, which allows for the control of interferons by plasmacytoid dendritic cells. Ermium Therapeutics has secured an exclusive worldwide license for its intellectual property from CNRS and University Paris Descartes, facilitated by Erganeo, which has aided in advancing the project within an academic environment. The company has also been recognized for its innovative approach, having won the innovation i-Lab 2019 award from the French Ministry of Research and Higher Education.
Vivasure Medical Limited is a medical device company based in Galway, Ireland, focused on the research, development, and manufacturing of arterial and venous closure devices utilizing its proprietary PerQseal technology. The company specializes in creating polymer implants and delivery systems aimed at facilitating minimally invasive vessel closures in cardiology, interventional radiology, and vascular surgery. Its flagship product is an absorbable patch-based large-bore percutaneous closure device, specifically designed to close large arteriotomies during transcatheter procedures like transcatheter aortic valve replacement and endovascular aneurysm repair. Established in 2008, Vivasure Medical aims to enhance patient outcomes in vascular access procedures through innovative medical solutions.
Calypso Biotech SA is an immunotherapy biotechnology company based in Plan-les-Ouates, Switzerland, founded in 2013 as a spin-off from Merck Serono. The company specializes in discovering and developing monoclonal antibodies aimed at treating immune pathologies, particularly for conditions with significant unmet medical needs, including severe gastrointestinal diseases. Calypso Biotech operates as a semi-virtual organization, leveraging a highly experienced management team with expertise in drug development. The company focuses on creating substantial value for investors through a portfolio of unique proprietary antibody candidates designed to control homeostasis and improve treatment outcomes for patients.
NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, established in 2012. The company specializes in the development of neurokinin (NK) receptor antagonists, focusing on treatments for conditions related to intense pruritus, particularly in patients undergoing targeted anti-cancer therapies. Its lead asset, orvepitant, is an oral NK-1 antagonist designed to alleviate this specific symptom. Additionally, NeRRe is advancing other candidates, including NT-814, a dual NK-1 and NK-3 antagonist, and NT-949, which is ready for Phase I trials. The company also has NT-432, a clinical candidate targeting NK-1 receptors. NeRRe Therapeutics aims to address unmet medical needs through its innovative therapeutic approaches.
Private Equity Round in 2021
Mainstay Medical Holdings plc is a medical device company based in Dublin, Ireland, with operations in the United States and Australia. Founded in 2008, the company specializes in developing and commercializing ReActiv8, an implantable neurostimulation system aimed at treating chronic low back pain. This innovative therapy is designed to restore control to the muscles that stabilize the lumbar spine, addressing a significant unmet need in the healthcare market. By collaborating with scientists and clinical experts, Mainstay Medical focuses on delivering effective solutions for patients suffering from debilitating pain, ultimately enhancing their quality of life.
XyloCor Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapies for cardiovascular diseases, particularly advanced coronary artery disease. Established in 2013 and based in Newtown Square, Pennsylvania, the company is working on innovative treatments such as XC001, an investigational gene therapy aimed at patients suffering from refractory angina who have limited treatment options, and XC002, which targets cardiac tissue regeneration in individuals with compromised heart function due to past heart attacks. XyloCor's approach involves stimulating the formation of new coronary blood vessels to improve blood supply to areas of the heart that are inadequately perfused, thereby offering potential pain relief and improved outcomes for patients who have exhausted conventional pharmacologic therapies.
Neurent Medical Limited is a medical device company based in Galway, Ireland, specializing in the development of innovative treatments for rhinitis. Founded in 2015, the company has created a single-use, minimally invasive device designed for ENT surgeons to address both allergic and non-allergic rhinitis. This hand-held, radio-frequency device is introduced through the nostrils into the nasal cavity under direct endoscopic visualization. It employs a microelectrode array to deliver targeted energy, interrupting the autonomic function of the mucosal structures in the nasal cavities. This approach helps reverse the inflammatory cascade, allowing for effective treatment in an office setting while minimizing the complications and costs commonly associated with traditional surgical procedures.
Neuromod Devices Limited is a medical device company based in Dublin, Ireland, established in 2010. It focuses on the research and development of neuromodulation treatments, specifically targeting chronic tinnitus, a condition that affects approximately 10% of adults. The company's flagship product, the mutebutton, is a bi-modal neuromodulation device designed to promote positive therapeutic changes in the nervous system. Neuromod aims to provide effective treatments for underserved patient populations suffering from chronic and debilitating conditions, enabling them to manage their health more effectively. The company has developed and patented its bi-modal neuromodulation technology, which is also being explored for other neurological disorders.
Priothera Ltd is a clinical-stage company focused on developing orally administered sphingosine 1 phosphate (S1P) receptor modulators aimed at treating haematological malignancies. Founded in 2020 and based in Dublin, Ireland, with an additional location in Saint Louis, France, the company seeks to improve patient outcomes by enhancing the curative potential of allogeneic hematopoietic stem cell transplantation. Its lead product, mocravimod, is designed to reduce the egress of specific T cell subsets from lymphatic tissues, thereby providing dual inhibition of graft versus host disease while promoting graft versus leukemia effects. Through this innovative approach, Priothera aims to deliver significant advancements in the treatment of patients with blood cancers.
Syndesi Therapeutics SA is a biopharmaceutical company based in Louvain-la-Neuve, Belgium, founded in 2018. The company focuses on developing drug molecules that modulate the synaptic vesicle protein SV2A, which is crucial for synaptic transmission—the process that facilitates communication between neurons in the brain. By regulating this transmission, Syndesi aims to create effective treatments for Alzheimer’s Disease and other cognitive impairment disorders. The company holds an exclusive license to its innovative platform technology from UCB, a leader in SV2A research. Through its efforts, Syndesi Therapeutics seeks to provide healthcare providers with advanced therapeutic options for managing these challenging conditions.
Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.
Neuromod Devices Limited is a medical device company based in Dublin, Ireland, established in 2010. It focuses on the research and development of neuromodulation treatments, specifically targeting chronic tinnitus, a condition that affects approximately 10% of adults. The company's flagship product, the mutebutton, is a bi-modal neuromodulation device designed to promote positive therapeutic changes in the nervous system. Neuromod aims to provide effective treatments for underserved patient populations suffering from chronic and debilitating conditions, enabling them to manage their health more effectively. The company has developed and patented its bi-modal neuromodulation technology, which is also being explored for other neurological disorders.
Velicept Therapeutics, Inc., a clinical development company, develops and commercializes drugs that have the potential to improve patients’ lives by transforming the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). Its lead program include Solabegron, a differentiated and selective compound that relaxes the bladder smooth muscle by stimulating beta 3-adrenoceptors, which is being investigated for OAB and IBS conditions that affect the quality of life. The company was founded in 2015 and is based in Malvern, Pennsylvania.
KANDY THERAPEUTICS LIMITED develops non-hormonal treatment for multiple symptoms of the menopause including hot flashes and night time awakening. The company offers NT-814, a drug for common, chronic debilitating female sex-hormone related treatment. It provides non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms, enabling patients to receive treatment, and reduce symptoms of hormone related conditions. The company was founded in 2017 and is based in Stevenage, United Kingdom. KANDY THERAPEUTICS LIMITED operates as a subsidiary of Bayer Aktiengesellschaft.
Neurent Medical Limited is a medical device company based in Galway, Ireland, specializing in the development of innovative treatments for rhinitis. Founded in 2015, the company has created a single-use, minimally invasive device designed for ENT surgeons to address both allergic and non-allergic rhinitis. This hand-held, radio-frequency device is introduced through the nostrils into the nasal cavity under direct endoscopic visualization. It employs a microelectrode array to deliver targeted energy, interrupting the autonomic function of the mucosal structures in the nasal cavities. This approach helps reverse the inflammatory cascade, allowing for effective treatment in an office setting while minimizing the complications and costs commonly associated with traditional surgical procedures.
MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.
Syndesi Therapeutics SA is a biopharmaceutical company based in Louvain-la-Neuve, Belgium, founded in 2018. The company focuses on developing drug molecules that modulate the synaptic vesicle protein SV2A, which is crucial for synaptic transmission—the process that facilitates communication between neurons in the brain. By regulating this transmission, Syndesi aims to create effective treatments for Alzheimer’s Disease and other cognitive impairment disorders. The company holds an exclusive license to its innovative platform technology from UCB, a leader in SV2A research. Through its efforts, Syndesi Therapeutics seeks to provide healthcare providers with advanced therapeutic options for managing these challenging conditions.
Mainstay Medical Holdings plc is a medical device company based in Dublin, Ireland, with operations in the United States and Australia. Founded in 2008, the company specializes in developing and commercializing ReActiv8, an implantable neurostimulation system aimed at treating chronic low back pain. This innovative therapy is designed to restore control to the muscles that stabilize the lumbar spine, addressing a significant unmet need in the healthcare market. By collaborating with scientists and clinical experts, Mainstay Medical focuses on delivering effective solutions for patients suffering from debilitating pain, ultimately enhancing their quality of life.
Syndesi Therapeutics SA is a biopharmaceutical company based in Louvain-la-Neuve, Belgium, founded in 2018. The company focuses on developing drug molecules that modulate the synaptic vesicle protein SV2A, which is crucial for synaptic transmission—the process that facilitates communication between neurons in the brain. By regulating this transmission, Syndesi aims to create effective treatments for Alzheimer’s Disease and other cognitive impairment disorders. The company holds an exclusive license to its innovative platform technology from UCB, a leader in SV2A research. Through its efforts, Syndesi Therapeutics seeks to provide healthcare providers with advanced therapeutic options for managing these challenging conditions.
NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, established in 2012. The company specializes in the development of neurokinin (NK) receptor antagonists, focusing on treatments for conditions related to intense pruritus, particularly in patients undergoing targeted anti-cancer therapies. Its lead asset, orvepitant, is an oral NK-1 antagonist designed to alleviate this specific symptom. Additionally, NeRRe is advancing other candidates, including NT-814, a dual NK-1 and NK-3 antagonist, and NT-949, which is ready for Phase I trials. The company also has NT-432, a clinical candidate targeting NK-1 receptors. NeRRe Therapeutics aims to address unmet medical needs through its innovative therapeutic approaches.
Inflazome Ltd. is a biotechnology company based in Dublin, Ireland, founded in 2016, that focuses on developing orally available drugs for inflammatory diseases by targeting the inflammasome. The company's innovative approach aims to block inflammasome signals, addressing the underlying causes of inflammation. Inflazome's portfolio includes treatments for a range of conditions, such as orphan diseases like Muckle-Wells syndrome and familial cold autoinflammatory syndrome, as well as chronic inflammatory disorders affecting the central nervous system, including Alzheimer's, Parkinson's, and multiple sclerosis. The company also targets systemic inflammatory diseases like cardiovascular and gastrointestinal issues, and explores applications in oncology and dermatology. Inflazome operates as a subsidiary of Roche Holding AG.
Vivasure Medical Limited is a medical device company based in Galway, Ireland, focused on the research, development, and manufacturing of arterial and venous closure devices utilizing its proprietary PerQseal technology. The company specializes in creating polymer implants and delivery systems aimed at facilitating minimally invasive vessel closures in cardiology, interventional radiology, and vascular surgery. Its flagship product is an absorbable patch-based large-bore percutaneous closure device, specifically designed to close large arteriotomies during transcatheter procedures like transcatheter aortic valve replacement and endovascular aneurysm repair. Established in 2008, Vivasure Medical aims to enhance patient outcomes in vascular access procedures through innovative medical solutions.
Chrono Therapeutics Inc., a digital transdermal drug delivery company, develops SmartStop, a digital nicotine replacement therapy. Its wearable solution tailors the timing and dose sizes of drugs, preempts predictable peak disease, and addiction symptoms with a device. The company was incorporated in 2003 and is based in Hayward, California.
Neuromod Devices Limited is a medical device company based in Dublin, Ireland, established in 2010. It focuses on the research and development of neuromodulation treatments, specifically targeting chronic tinnitus, a condition that affects approximately 10% of adults. The company's flagship product, the mutebutton, is a bi-modal neuromodulation device designed to promote positive therapeutic changes in the nervous system. Neuromod aims to provide effective treatments for underserved patient populations suffering from chronic and debilitating conditions, enabling them to manage their health more effectively. The company has developed and patented its bi-modal neuromodulation technology, which is also being explored for other neurological disorders.
Neuravi Limited is a medical device company based in Galway, Ireland, focused on developing clot retrieval devices to restore blood flow in patients who have experienced ischemic strokes caused by arterial blockages in the brain. The company offers the EmboTrap revascularization devices, which are designed for the treatment of acute ischemic strokes and are available in several European countries, including Belgium, Denmark, France, Germany, and Spain. Founded in 2009, Neuravi operates in the emerging neurointerventional device market and collaborates with researchers and clinicians to advance treatment solutions for this serious condition. As of April 2017, Neuravi is a subsidiary of DePuy Ireland Unlimited Company.
Civitas Therapeutics is a biopharmaceutical company dedicated to developing therapies for pulmonary delivery. The company focuses on creating innovative treatments for central nervous system and respiratory disorders, with a particular emphasis on conditions such as multiple sclerosis and spinal cord injuries. Civitas Therapeutics aims to improve the health and quality of life for patients across the United States through its specialized drug delivery systems.
Chrono Therapeutics Inc., a digital transdermal drug delivery company, develops SmartStop, a digital nicotine replacement therapy. Its wearable solution tailors the timing and dose sizes of drugs, preempts predictable peak disease, and addiction symptoms with a device. The company was incorporated in 2003 and is based in Hayward, California.
Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.
Civitas Therapeutics is a biopharmaceutical company dedicated to developing therapies for pulmonary delivery. The company focuses on creating innovative treatments for central nervous system and respiratory disorders, with a particular emphasis on conditions such as multiple sclerosis and spinal cord injuries. Civitas Therapeutics aims to improve the health and quality of life for patients across the United States through its specialized drug delivery systems.
Trino is a drug discovery and early drug development company focused on anti-inflammatory therapeutics. The company is developing drug candidates from a novel, proprietary, class of drugs based on indane dimers derived from a Taiwanese fern. Its lead candidate is a potential first-in-class drug for the treatment of inflammatory bowel disease (IBD), which could be used in both ulcerative colitis (UC) and Crohn’s disease (CD). Trino’s drug class also offers promising candidates with a broad anti-inflammatory activity that could be suitable for applications in dermatology, pulmonary and auto-immune disease.
Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.
Mainstay Medical Holdings plc is a medical device company based in Dublin, Ireland, with operations in the United States and Australia. Founded in 2008, the company specializes in developing and commercializing ReActiv8, an implantable neurostimulation system aimed at treating chronic low back pain. This innovative therapy is designed to restore control to the muscles that stabilize the lumbar spine, addressing a significant unmet need in the healthcare market. By collaborating with scientists and clinical experts, Mainstay Medical focuses on delivering effective solutions for patients suffering from debilitating pain, ultimately enhancing their quality of life.
Neuravi Limited is a medical device company based in Galway, Ireland, focused on developing clot retrieval devices to restore blood flow in patients who have experienced ischemic strokes caused by arterial blockages in the brain. The company offers the EmboTrap revascularization devices, which are designed for the treatment of acute ischemic strokes and are available in several European countries, including Belgium, Denmark, France, Germany, and Spain. Founded in 2009, Neuravi operates in the emerging neurointerventional device market and collaborates with researchers and clinicians to advance treatment solutions for this serious condition. As of April 2017, Neuravi is a subsidiary of DePuy Ireland Unlimited Company.
Cappella, Inc., a Dover, Del.- and Galway, Ireland-based medical device company that is developing novel solutions for the treatment of Complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. The company was founded in 2004 by Antonio Columbo, M.D., Chief of Invasive Cardiology at San Raffaele Hospital in Milan, Italy, and Ascher Shmulewitz, M.D., Ph.D., a cardiologist, medical device entrepreneur and founder of NeoVision, Xcardia and Labcoat Ltd., and established its European headquarters in Galway in 2005.
Genable Technologies Limited is a bio-pharmaceutical company based in Dublin, Ireland, focused on developing gene therapies for autosomal dominant genetic diseases. The company's primary product, RhoNova, targets rhodopsin-linked autosomal dominant retinitis pigmentosa, a progressive genetic condition leading to blindness caused by mutations in the RHO gene. Genable employs a unique approach that utilizes adeno-associated virus (AAV) vectors to deliver RNA interference molecules, effectively suppressing both faulty and normal gene copies while replacing them with a modified gene that produces a normal protein. This method, known as suppression and replacement, addresses the challenge of mutation variability in dominant diseases. Genable Technologies is backed by a strong portfolio of patents in the United States, Europe, and worldwide, reflecting its innovative contributions to the field of gene therapy.
Amarin Corporation plc is a pharmaceutical company dedicated to developing and commercializing therapeutics for cardiovascular diseases in the United States. Its primary product, Vascepa, is a prescription omega-3 fatty acid capsule designed to reduce triglyceride levels in adults with severe hypertriglyceridemia. The company is also conducting research on the REDUCE-IT study, which targets patients with high triglyceride levels who are undergoing statin therapy. Amarin markets its products primarily to wholesalers and specialty pharmacy providers, utilizing a direct sales force. The company has partnered with Mochida Pharmaceutical Co., Ltd. to further develop and commercialize products based on the active ingredient in Vascepa, eicosapentaenoic acid. Founded in 1989 and headquartered in Dublin, Ireland, Amarin has a research and development facility in Mystic, Connecticut, and focuses on lipid science to enhance cardiovascular disease management.
Palyon Medical Corporation is a medical device company developing technologies for the treatment of chronic pain, spasticity and other neurological diseases.
Cappella, Inc., a Dover, Del.- and Galway, Ireland-based medical device company that is developing novel solutions for the treatment of Complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. The company was founded in 2004 by Antonio Columbo, M.D., Chief of Invasive Cardiology at San Raffaele Hospital in Milan, Italy, and Ascher Shmulewitz, M.D., Ph.D., a cardiologist, medical device entrepreneur and founder of NeoVision, Xcardia and Labcoat Ltd., and established its European headquarters in Galway in 2005.
Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.
Vivasure Medical Limited is a medical device company based in Galway, Ireland, focused on the research, development, and manufacturing of arterial and venous closure devices utilizing its proprietary PerQseal technology. The company specializes in creating polymer implants and delivery systems aimed at facilitating minimally invasive vessel closures in cardiology, interventional radiology, and vascular surgery. Its flagship product is an absorbable patch-based large-bore percutaneous closure device, specifically designed to close large arteriotomies during transcatheter procedures like transcatheter aortic valve replacement and endovascular aneurysm repair. Established in 2008, Vivasure Medical aims to enhance patient outcomes in vascular access procedures through innovative medical solutions.